This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Natural Alternatives International, Inc. Announces Fiscal 2010 Q2 Results

SAN MARCOS, Calif., Feb. 16 /PRNewswire-FirstCall/ -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $674,000 or $0.10 per diluted share on net sales from continuing operations of $17.2 million for the quarter ended December 31, 2009.  

Net sales from continuing operations during the quarter ended December 31, 2009 decreased $367,000 from $17.6 million reported in the comparable prior year period.  Operating income from continuing operations increased to $736,000 for the second quarter of fiscal 2010 as compared to an operating loss in the comparable prior year quarter of $2.1 million. The improvement in operating income from continuing operations was primarily attributable to lower raw material costs, decreased manufacturing labor and overhead expenses, and reductions in selling and general administrative expenses, including restructuring charges, associated with our cost reduction programs implemented during fiscal 2009.

For the quarter ended December 31, 2009, contract manufacturing sales declined $303,000 or 1.8% from the comparable quarter last year due primarily to lower sales volumes from various customers and the discontinuance of a customer relationship during the first quarter of fiscal 2010. Net sales from our branded products totaled $574,000 for the second quarter of fiscal 2010 compared to $638,000 for the prior year period. This decrease was associated with the continued softening of our Pathway to Healing® product line sales.  During late fiscal 2009 we revamped our Dr. Cherry website and increased our direct-to-consumer marketing and advertising efforts, which helped reduce the historical sales decline for these products during the second quarter of fiscal 2010. During late fiscal 2010 we intend to further increase our Dr. Cherry marketing and advertising efforts and plan to re-launch various product offerings including new formulations, labeling and packaging in an effort to expand our future sales opportunities.

Net income from continuing operations in the second quarter of fiscal 2010 was $614,000 or $0.09 per diluted share compared to a net loss of $2.5 million or $0.36 per share in the second quarter of fiscal 2009.

During the second quarter of fiscal 2010 we also generated net income from discontinued operations of $60,000 or $0.01 per diluted share as compared to a net loss of $756,000 or $0.11 per share in the second quarter of fiscal 2009.  The net loss from discontinued operations in the prior year quarter was primarily attributable to a deferred tax asset valuation allowance totaling $621,000. On July 31, 2009, we sold substantially all of the remaining assets of Real Health Laboratories (RHL) and anticipate the remaining wind-down business activity of RHL will be completed during the second half of fiscal 2010.  

As of December 31, 2009, NAI had cash and certificates of deposit of $5.3 million and working capital of $15.9 million compared to $4.7 million and $13.9 million, respectively, as of June 30, 2009.  As of December 31, 2009, we had $3.8 million available under our working capital line of credit.

Mark A. LeDoux, Chief Executive Officer, stated, "Our continued focus on operational improvements and efficiencies has demonstrated positive results.  We have found ways of doing more with less and intend to continue to focus on adding value to our client partnerships. We also have expanded our efforts and footprint in generating commercial value from our patent estate with our CarnoSyn® beta-alanine compound. We are evaluating new packaging systems to improve customer retention and compliance with daily regimens of supplementation and provide portability to consumers – further enhancing customer loyalty and helping improve nutritive status."

NAI, headquartered in San Marcos, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at

This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, including the amount of our future revenue and profits and our future financial condition, the timing of the completion of the wind-down of RHL, and our ability to further reduce operating costs, reduce our debt, expand and retain our contract manufacturing business, grow our Dr. Cherry business and the timing of our increased marketing efforts and the re-launch of this product line, develop, maintain or increase sales to new and existing customers, expand the commercial value of our patent estate, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
NAII $6.25 1.79%
AAPL $109.50 -1.16%
FB $92.47 0.08%
GOOG $639.16 -0.50%
TSLA $226.72 -2.26%


Chart of I:DJI
DOW 17,050.75 +138.46 0.82%
S&P 500 1,995.83 +15.91 0.80%
NASDAQ 4,810.7880 +19.6360 0.41%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs